Specifications tableSubject area*Chemistry, Biology*More specific subject area*Organic chemistry, Pharmacology*Type of data^*1*^*H and*^*13*^*C NMR spectra, HPLC-MS chromatograms, column tables*How data was acquired*NMR Bruker DRX-400 spectrometer at 25 °C, HPLC-MS*LTQ XL linear ion trap mass spectrometer coupled with Accela LC system (Thermo Fisher Scientific, Waltham, MA, USA).*, "Isolated working heart system".*Data format*Raw, filtered and analyzed*Experimental factors*Initial compounds were purchased, the intermediates and the end-product were synthesized as described in the original paper.*Experimental features*New compounds have been characterized by spectrometric methods and an ex vivo technique on rat hearts*Data source location- Department of Pharmacology and Department of Bioanalytical Chemistry, Nagyerdei Krt 98, H-4032 Debrecen, Hungary\
- Department of Pharmaceutical Chemistry, Faculty of Pharmacy, University of Debrecen, Egyetem tér 1, H-4032 Debrecen, HungaryData accessibility*Data are provided with this article.*Related research articleK. Szoke, A. Czompa, I. Lekli, P. Szabados-Furjesi, M. Herczeg, M. Csavas, A. Borbas, P. Herczegh, A. Tosaki, A new, vasoactive hybrid aspirin containing nitrogen monoxide-releasing molsidomine moiety, Eur. J. Pharm. Sci., 131, 2019, 159--166 [@bib1].**Value of the data**•The NMR spectra can be used for structure elucidation of similar synthetic compounds.•Dataset of stability tests could be used to pretest the degradation profiles of molecules planned to try in vivo circumstances.•The cardiac functions detailed here are important indicator related to the contractile activity of the myocardium (see [Fig. 2](#fig2){ref-type="fig"}).

1. Data {#sec1}
=======

Spectra from ^1^H and ^13^C NMR measurements are reported to prove the structure of the synthesized compounds [@bib1] (see [Fig. 1](#fig1){ref-type="fig"}, [Fig. 2](#fig2){ref-type="fig"}, [Fig. 4](#fig4){ref-type="fig"}, [Fig. 5](#fig5){ref-type="fig"}, [Fig. 6](#fig6){ref-type="fig"}, [Fig. 7](#fig7){ref-type="fig"}, [Fig. 8](#fig8){ref-type="fig"}, [Fig. 9](#fig9){ref-type="fig"}). HPLC-MS measurements were used to study the oxidative stability of the compound ERJ-500, representative total ion chromatogram of the oxidation by synthetic porphyrin and the Chemical Fenton System can be seen ([Fig. 10](#fig10){ref-type="fig"}, [Fig. 11](#fig11){ref-type="fig"}). Cardiac parameters (*aorta flow, aortic pressure, derivated aortic pressure, and cardiac output*) were registered ([Fig. 12](#fig12){ref-type="fig"}) in "isolated working hearts" treated with **ERJ-500**.Fig. 1Structure of ERJ-500.Fig. 1Fig. 2^1^H NMR spectra of compound **5**.Fig. 2Fig. 3^13^C NMR spectra of compound **5**.Fig. 3Fig. 4^1^H NMR spectra of compound **6**.Fig. 4Fig. 5^13^C NMR spectra of compound **6**.Fig. 5Fig. 6^1^H NMR spectra of compound **7**.Fig. 6Fig. 7^13^C NMR spectra of compound **7**.Fig. 7Fig. 8^1^H NMR spectra of compound **ERJ-500**.Fig. 8Fig. 9^13^C NMR spectra of compound **ERJ-500**.Fig. 9Fig. 10Representative total ion chromatogram of the oxidation by synthetic porphyrin. On the control chromatogram (red) the peak at 6.59 represents **ERJ-500**. After oxidation (green chromatogram) the peak of **ERJ-500** at 6.58 remained unchanged.Fig. 10Fig. 11Representative total ion chromatogram of the oxidation by the Chemical Fenton System. On the control chromatogram (red) the peak at 6.54 represents **ERJ-500**. After oxidation (green chromatogram) the peak of **ERJ-500** at 6.53 remained unchanged.Fig. 11Fig. 12Myocardial function. The results show aorta flow, aortic pressure, derivated aortic pressure, and cardiac output in control and ERJ-500 treated hearts.Fig. 12

1.1. Characterization of new compounds {#sec1.1}
--------------------------------------

The ^1^H NMR (400 MHz) and ^13^C NMR (101 MHz) spectra were recorded with a Bruker DRX-400 spectrometer at 25 °C. Chemical shifts are referenced to Me~4~Si (0.00 ppm for ^1^H) and to the residual solvent signals (CDCl~3~: 77.1 for ^13^C).

1.2. Compound 5 {#sec1.2}
---------------

^1^H NMR (400 MHz, CDCl~3~): *δ* 8.03 (dd, *J* = 7.8 Hz, *J* = 1.8 Hz, 1H, arom), 7.53 (td, *J* = 7.8 Hz, *J* = 1.8 Hz, 1H, arom), 7.47--7.45 (m, 6H, arom), 7.30--7.19 (m, 10H, arom), 7.08 (dd, *J* = 8.1 Hz, *J* = 0.8 Hz, 1H), 4.41--4.39 (m, 2H, TEG-*C*H~2~), 3.78--3.76 (m, 2H, TEG-*C*H~2~), 3.70--3.65 (m, 10H, 5 × TEG-*C*H~2~), 3.23 (t, *J* = 5.2 Hz, 2H, TEG-*C*H~2~), 2.34 (s, 3H, *C*H~3~ Ac); ^13^C NMR (101 MHz, CDCl~3~): *δ* 169.9 (1C, C~q~ Ac), 164.5 (1C, *C*OO), 150.8 (1C, C~q~ arom), 144.2 (3C, C~q~ arom), 134.0, 132.0, 128.8, 127.9, 127.0, 126.1, 123.9 (19C, arom), 123.3 (1C, Cq arom), 86.6 (1C, C~q~ Tr), 70.9, 70.8, 70.7, 69.2, 64.4, 63.4 (8C, 8 × TEG-*C*H~2~), 21.1 (1C, *C*H~3~ Ac).

1.3. Compound 6 {#sec1.3}
---------------

^1^H NMR (400 MHz, CDCl~3~): *δ* 8.05 (dd, *J* = 7.8 Hz, *J* = 1.6 Hz, 1H, arom), 7.56 (td, *J* = 7.9 Hz, *J* = 1.6 Hz, 1H, arom), 7.32 (td, *J* = 7.6 Hz, *J* = 1.2 Hz, 1H, arom), 7.11 (dd, *J* = 8.1 Hz, *J* = 1.2 Hz, 1H, arom), 4.45--4.43 (m, 2H, TEG-*C*H~2~), 3.81--3.78 (m, 2H, TEG-*C*H~2~), 3.74--3.65 (m, 10H, 5 × TEG-*C*H~2~), 3.60--3.58 (m, 2H, TEG-*C*H~2~), 2.62 (s, 1H, TEG-O*H*), 2.36 (s, 3H, *C*H~3~ Ac); ^13^C NMR (101 MHz, CDCl~3~): *δ* 169.9 (1C, C~q~ *C*OO), 164.5 (1C, C~q~ Ac), 150.8 (1C, C~q~ arom), 134.1, 132.0, 126.1, 123.9 (4C, arom), 123.2 (1C, C~q~ arom), 72.5, 70.8, 70.7, 70.6, 70.4, 69.2, 64.3, 61.8 (8C, 8 × TEG-*C*H~2~), 21.1 (1C, *C*H~3~ Ac).

1.4. Compound 7 {#sec1.4}
---------------

^1^H NMR (400 MHz, CDCl~3~): *δ* 8.41 (s, 1H, C*H* sydnone), 8.27 (d, *J* = 9.1 Hz, 2H, arom), 7.42 (d, *J* = 9.1 Hz, 1H, arom), 3.87--3.85 (m, 2H, *C*H~2~ morpholine), 3.64--3.61 (m, 2H, *C*H~2~ morpholine); ^13^C NMR (101 MHz, CD~3~OD): *δ* 183.5 (1C, C~q~ carbamate), 167.0 (1C, C~q~ sydnone), 134.5, 132.1, (4C, arom), 125.3 (1C, *C*H), 74.3, 62.9 (4C, 4 × morfoline-*C*H~2~).

1.5. Compound ERJ-500 {#sec1.5}
---------------------

^1^H NMR (400 MHz, CDCl~3~): *δ* 8.03 (dd, *J* = 7.9 Hz, *J* = 1.7 Hz, 1H, arom), 7.70 (s, 1H, C*H* sydnone), 7.56 (ddd, *J* = 8.1, 7.4, 1.8 Hz, 1H, arom), 7.31 (td, *J* = 7.7 Hz, 1.1 Hz, 1H, arom), 7.10 (dd, *J* = 8.1 Hz, *J* = 1.1 Hz, 1H, arom), 4.43--4.41 (m, 2H, *C*H~2~ morpholine), 4.26--4.24 (m, 2H, *C*H~2~ morpholine), 3.94--3.92 (m, 4H, 2 × TEG-*C*H~2~), 3.80--3.78 (m, 2H, *C*H~2~ morpholine), 3.74--3.72 (m, 2H, *C*H~2~ morpholine), 3.68--3.63 (m, 8H, 4 × TEG-*C*H~2~), 3.51--3.49 (m, 4H, 2 × TEG-*C*H~2~), 2.35 (s, 3H, *C*H~3~ Ac); ^13^C NMR (101 MHz, CDCl~3~): *δ* 174.2 (1C, C~q~ carbamate), 169.7 (1C, C~q~ COO), 164.4 (1C, C~q~ Ac), 161.2 (1C, C~q~ sydnone), 150.6 (1C, C~q~ arom), 133.8, 131.8, 125.9, 123.7 (4C, arom), 123.2 (1C, C~q~ arom), 70.6, 70.5, 69.3, 69.0, 65.4, 64.6, 64.3, 54.6 (13C, 1 × sydnone-*C*, 4 × morpholine-*C*H~2~, 8 × TEG-*C*H~2~), 20.9 (1C, *C*H~3~ Ac).

1.6. Representative chromatograms of oxidative stability assays {#sec1.6}
---------------------------------------------------------------
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2. Experimental design, materials and methods {#sec2}
=============================================

2.1. LC-MS measurements {#sec2.1}
-----------------------

The reaction mixture was analyzed with an LTQ-XL linear ion trap mass spectrometer coupled with the Accela LC system (Thermo Fisher Scientific, Waltham, MA, USA). The HPLC separation was performed using a Kinetex XB-C18 2.6 μm column, 0.1% formic acid in water, and ACN with 0.1% formic acid with gradient elution, and the flow rate was set to 300 μL/min. The method parameters for mass spectrometry were the followings: 35 a.u. sheath gas flow rate, 5000 V spray voltage, 275 °C capillary temperature, 31 V capillary voltage, 150 V tube lens voltage, and 34 V skimmer voltage.

2.2. Oxidation by synthetic porphyrin and the chemical Fenton system {#sec2.2}
--------------------------------------------------------------------

Two reactions were carried out to test the stability of ERJ-500 molecule under oxidative conditions, based on the method as reported by Csepanyi et al. [@bib2] recently, with minor modifications as follows: 50 μl of ERJ-500 dissolved in acetonitrile was used for synthetic porphyrin oxidation in 10 mM concentration. 400 μl of **ERJ-500** in 2.5 mM concentration for the Fenton reaction. Samples were drawn at 1 h in the Fenton reactions prior to injecting them instantly to the HPLC and further investigation. Reaction mixtures for blank contained acetonitrile only without **ERJ-500**. The control mixtures contained no peroxide.

2.3. Isolated working heart preparation to assess cardiac parameters {#sec2.3}
--------------------------------------------------------------------

To measure cardiac function (Aortic flow, Aortic pressure, Derivated aortic pressure, and Cardiac output), isolated working heart preparations were carried out based on a previously described method by Czompa et al. [@bib3] on Sprague Dawley female rat hearts (n = 11 in the control group, n = 6 in the treated group). After completing the isolated working heart preparation procedure followed by 10 min washout period, and aorta flow, aortic pressure, derivated aortic pressure, and cardiac output were registered ([Fig. 12](#fig12){ref-type="fig"}). Cardiac output was calculated by the sum of aortic and coronary flow represented in the associated research article [@bib1]. In the treated group, **ERJ-500** was added to the KHB buffer by a dilution of a previously prepared stock solution leading to a 100 μM concentration of **ERJ-500** in the inflow line. The molecule-containing KHB buffer was presented after the washout and baseline registration period for 5 min, followed by a 30 min ischemia and 90 min of reperfusion.
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